• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Annovis Bio Inc (NY: ANVS )

    9.280 -0.270 (-2.83%)
    Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Annovis Bio Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
    From FN Media Group LLC
    Via GlobeNewswire
    Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
    EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Peering Into Annovis Bio's Recent Short Interest
    Via Benzinga
    Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
    From FN Media Group LLC
    Via GlobeNewswire
    BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Featured in Latest Bell2Bell Podcast, Recorded Live at AAIC 2024
    Via Investor Brand Network
    Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?
    ANVS stock closed up more than 75% today after Annovis announced encouraging clinical trial results for its Parkinson's drug, buntanetap. 
    Via InvestorPlace
    Peering Into Annovis Bio's Recent Short Interest
    Via Benzinga
    Annovis Bio Inc. (NYSE: ANVS) Announces FDA Approval to Transition to New Form of Buntanetap for Future Clinical Trials
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain Injury with Its Lead Drug Candidate
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members
    Via Investor Brand Network
    Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease
    Via Investor Brand Network
    Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team
    Via Investor Brand Network
    Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family 
    Via Benzinga
    What's Going On With Annovis Shares Today?
    Annovis Bio shares rise in premarket trading on positive Phase III Parkinson's study results for buntanetap, showing cognitive improvements and stability compared to placebo. 
    Via Benzinga
    Tesla, Paramount Global, Annovis Bio, Eli Lilly, Amazon: Why These 5 Stocks Are On Investors' Radars Today
    On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in positive territory. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    What's Going With Annovis Bio Shares Tuesday?
    Annovis announced new data from its Phase III Parkinson's study. The study showed improvements on the Unified Parkinson's Disease Rating Scale following treatment with Buntanetap. 
    Via Benzinga
    BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study, Schedules Webcast
    Via Investor Brand Network
    Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease
    Via Investor Brand Network
    BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Provisional Patent Covering Manufacturing Process of New Solid Forms of Buntanetap
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Upcoming Investor Webcast Focused on PD, Lead Drug Candidate
    Via Investor Brand Network
    BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024
    Via Investor Brand Network
    BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call
    Via Investor Brand Network
    Annovis Bio Inc. (NYSE: ANVS) Is ‘One to Watch’
    Via Investor Brand Network
    BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate
    Via Investor Brand Network
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.